|By Marketwired .||
|August 16, 2013 08:00 AM EDT||
NISKAYUNA, NY and IRVINE, CA -- (Marketwired) -- 08/16/13 -- Masimo (NASDAQ: MASI) and Pathways Nursing & Rehabilitation Center, specializing in on-site medical and rehabilitation treatments to optimize recovery for sub acute, traumatic brain injury, ventilator-dependent, and pediatric patients, jointly announce that Pathways has converted to Masimo SET® pulse oximetry and sensor technologies, the standard-of-care at leading health organizations worldwide.
Pathways' conversion to Masimo SET® pulse oximetry is in keeping with the healthcare organization's dedication to excellence in care and delivering the best possible results for its patients.
The performance of Masimo SET® pulse oximetry is proven by more than 100 independent and objective studies and thousands of clinical evaluations. Masimo SET® is trusted by clinicians to safely monitor more than 100 million patients each year and is used hospital-wide by eight of the top 10 U.S. hospitals on the U.S. News & World Report Best Hospitals Honor Roll (2013-2014). Compared to other pulse oximeters during patient motion and low perfusion, Masimo SET® provides measurements when other pulse oximeters cannot, dramatically reduces false alarms (specificity), and accurately detects true alarms (sensitivity)(1,2) that can indicate a deteriorating patient. Most importantly, Masimo SET® pulse oximetry has been shown to be the only proven technology to improve patient outcomes by helping clinicians reduce retinopathy of prematurity (ROP)(3) in neonates, screen newborns for critical congenital heart disease (CCHD),(4,5) reduce ventilator weaning time and arterial blood gas measurements in the ICU,(6) and save lives and costs while reducing rapid response activations and intensive care unit transfers on the general floor.(2)
"We have this one little girl we affectionately call 'wild woman'," says Sandy Dykens, Director of Respiratory at Pathways. "She was weaned off a ventilator here, and she is very active -- always grabbing things and moving around. Because she is so active, the alarm on her old pulse oximeter kept going off with a false oxygen desaturation, and we kept running to her bedside to make sure she was all right."
"With Masimo you get a truer reading and far fewer false alarms, so now when we do hear alarms, we don't risk missing something that really needs our attention," Dykens adds. "'Wild woman' is still very active. But when we go to her bedside these days, it's to see her playing, not rushing in to expect to see her crashing. And her wellbeing is so much better because of it. She can be active without staff interrupting her play to check on her sensors. She has more of a normal childhood. We're so appreciative of this."
"We are happy to have forged this great partnership with Pathways, which like other great healthcare organizations is demonstrating its commitment to patient safety and care by taking advantage of our breakthrough measure-through motion and low perfusion pulse oximetry technology," said Masimo Founder and CEO Joe Kiani. "We value this relationship with Pathways, and together look forward to helping their skilled and dedicated staff meet and exceed their patient-care needs."
About Pathways Nursing & Rehabilitation Center
Pathways Nursing and Rehabilitation Center is a unique and comprehensive rehabilitation center serving TBI, Pediatric and Sub Acute patients. Located in the beautiful Mohawk Valley, Pathways is a 112-bed facility, providing on-site medical and rehabilitation treatments to optimize recovery for sub acute, TBI, Ventilator-dependent and pediatric patients. Our caring professionals provide comprehensive individual care plans to ensure the highest quality of care to all of our patients. For more information, please visit www.pathways-rehab.com
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions that the hospital-wide conversion ensures that all Pathways Nursing & Rehabilitation Center patients will be cared for using the most technologically and clinically-advanced noninvasive patient monitoring solutions available; risks related to our belief that Masimo SET provides real-time results for all patients to help clinicians to more rapidly assess, diagnose, and treat every patient; risks related to our assumptions regarding the repeatability of clinical results; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.
1 Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers".J Clin Anesth. 2012 Aug;24(5):385-91.
2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here.
3 Castillo A, et al. Acta Paediatr. 2011 Feb.;100(2):188-92.
4 de-Wahl Granelli A., et al. BMJ. 2009 Jan 8;338.
5 Ewer A, et al. Health Technol Assess. 2012;16(2):1-184.
6 Durbin, et al. Critical Care Medicine. 2002 Aug.;30(8): 1735 to 1740.